Daiichi Sankyo Opens New Affiliate for Oncology in Greece
July 10 2024 - 6:06AM
Business Wire
- Newly established affiliate in Greece demonstrates Daiichi
Sankyo’s ongoing commitment to serve as many people living with
cancer as possible
- In Greece, breast cancer is the leading cause of cancer-related
death among women and lung cancer among men1
- Greece’s geographical location offers a unique opportunity to
facilitate regional cooperation across Europe
Daiichi Sankyo (TSE: 4568) today announced that it has opened a
new affiliate for its oncology business in Athens, Greece. The
establishment highlights the company’s strong commitment to
addressing treatment needs of people living with cancer in the
European region. Thomais Konstantopoulou has been appointed Country
Manager, Daiichi Sankyo Greece Single Member S.A.
“We are very happy to open yet another new affiliate in Europe
to bring our innovative medicines to patients who can benefit from
them. To have representation in a country is the best way of doing
this,” said Thomais Konstantopoulou, Country Manager, Daiichi
Sankyo Greece. “Our decision to establish a presence in Greece
stems from our deep-rooted commitment to serving as many patients
with cancer as possible with our innovative portfolio, aiming to
improve outcomes and quality of life. It also is linked to a
continuous effort of multiple stakeholders that elevates oncology
in the country’s healthcare agenda and promotes active dialogue.
Daiichi Sankyo is investing in Greece, which aligns with the
country’s ambition to create conditions that foster innovation,
talent retention, technology advancement and economic growth. We
are focused on advancing meaningful innovation and creating jobs in
a sustainable manner.”
Daiichi Sankyo has affiliates in 14 European countries,
alongside representations in Norway, Finland, Sweden and
Luxembourg. Europe has always been a focus for the company’s
medicines, as well as a key region for continuous investment. With
20 research and development sites across 12 countries, Daiichi
Sankyo utilizes a global network to drive innovation. Currently,
the company is focused on developing antibody drug conjugates
(ADCs), which are targeted cancer medicines that combine
target-specificity and anti-tumor activity in a single
molecule.
“From pursuing new medicines and new methods of drug discovery
and delivery to achieving excellence throughout our organization by
continuously examining new ideas, innovation is paramount for all
we do,” said Dr. Dimitrios Krikelis, Head of Medical Affairs,
Daiichi Sankyo Greece. “Even before the establishment of the Greek
affiliate, Daiichi Sankyo has been partnering with the local
oncology community through our clinical development program. We are
fortunate to have physicians with a wealth of clinical expertise
and a vibrant research community in Greece.”
Daiichi Sankyo aims to be an active contributor to the Greek
healthcare ecosystem by partnering with the scientific community,
governmental organizations and patient advocacy groups in order to
provide value to patients, healthcare professionals and health
authorities.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company
contributing to the sustainable development of society that
discovers, develops and delivers new standards of care to enrich
the quality of life around the world. With more than 120 years of
experience, Daiichi Sankyo leverages its world-class science and
technology to create new modalities and innovative medicines for
people with cancer, cardiovascular and other diseases with high
unmet medical need. For more information, please visit
www.daiichi-sankyo.eu.
HQ/ONP/07/24/0007
_______________________________
1
https://www.jto.org/article/S1556-0864(20)31099-6/fulltext
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709254444/en/
Daiichi Sankyo Europe GmbH Giedre Petkevice
press@daiichi-sankyo.eu +49 151 1 6817 651